ATE369126T1 - Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung - Google Patents

Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung

Info

Publication number
ATE369126T1
ATE369126T1 AT00939884T AT00939884T ATE369126T1 AT E369126 T1 ATE369126 T1 AT E369126T1 AT 00939884 T AT00939884 T AT 00939884T AT 00939884 T AT00939884 T AT 00939884T AT E369126 T1 ATE369126 T1 AT E369126T1
Authority
AT
Austria
Prior art keywords
combination therapy
weight reduction
obesity treatment
phentermine
weight loss
Prior art date
Application number
AT00939884T
Other languages
English (en)
Inventor
Thomas Najarian
Original Assignee
Vivus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivus Inc filed Critical Vivus Inc
Application granted granted Critical
Publication of ATE369126T1 publication Critical patent/ATE369126T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT00939884T 1999-06-14 2000-06-14 Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung ATE369126T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13902299P 1999-06-14 1999-06-14
US17856300P 2000-01-26 2000-01-26
US18126500P 2000-02-09 2000-02-09

Publications (1)

Publication Number Publication Date
ATE369126T1 true ATE369126T1 (de) 2007-08-15

Family

ID=27385274

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00939884T ATE369126T1 (de) 1999-06-14 2000-06-14 Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung

Country Status (10)

Country Link
EP (5) EP1187603B1 (de)
AT (1) ATE369126T1 (de)
AU (1) AU770068B2 (de)
CA (2) CA2686633A1 (de)
CY (1) CY1106974T1 (de)
DE (1) DE60035870T2 (de)
DK (1) DK1187603T3 (de)
ES (4) ES2291215T3 (de)
PT (1) PT1187603E (de)
WO (1) WO2000076493A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553818B2 (en) 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7659256B2 (en) 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US6852701B2 (en) 2000-07-07 2005-02-08 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for preventing the development of Type II diabetes mellitus and Syndrome X
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
AU2002253838B2 (en) * 2000-10-30 2006-11-09 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising anti-diabetic and anticonvulsant agents
EP1345602B1 (de) * 2000-11-30 2010-07-21 Novodermix International Limited Heilung von wunden
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
MXPA04011203A (es) 2002-05-17 2005-07-14 Univ Duke Metodo para tratar la obesidad.
US20070036732A1 (en) * 2002-12-13 2007-02-15 Reza Eivaskhani Stable topiramate formulations
WO2004096201A1 (en) 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
WO2005070461A2 (en) * 2004-01-13 2005-08-04 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
KR20080012360A (ko) 2005-05-20 2008-02-11 얀센 파마슈티카 엔.브이. 설파미드 유도체의 제조 방법
MX337422B (es) 2005-11-22 2016-03-04 Orexigen Therapeutics Inc Composiciones y metodos para incrementar la sencibilidad a la insulina.
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
EA200870556A1 (ru) 2006-05-19 2009-06-30 Янссен Фармацевтика Н.В. Комбинированная терапия в лечении эпилепсии и родственных расстройств
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US7780730B2 (en) 2006-09-25 2010-08-24 Iyad Saidi Nasal implant introduced through a non-surgical injection technique
ATE460925T1 (de) * 2006-11-09 2010-04-15 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
KR20090090316A (ko) 2006-11-09 2009-08-25 오렉시젠 세러퓨틱스 인크. 체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법
AU2014213552B2 (en) * 2007-06-13 2016-11-24 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
US8071557B2 (en) 2007-06-13 2011-12-06 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
BRPI0915890A2 (pt) 2008-06-23 2015-11-03 Janssen Pharmaceutica Nv forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US9597220B2 (en) 2008-11-19 2017-03-21 Spirox, Inc. Apparatus and methods for correcting nasal valve collapse
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
WO2013028909A1 (en) * 2011-08-25 2013-02-28 Sova Pharmaceuticals, Inc. Combination therapy for the treatment of sleep-related breathing disorders
KR20150016405A (ko) 2012-06-06 2015-02-11 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
EP3400906A1 (de) 2013-02-27 2018-11-14 Spirox, Inc. Nasenimplantate
WO2014134477A1 (en) * 2013-02-28 2014-09-04 Livelight Llc Methods and systems for treating overweight individuals
US10226062B2 (en) 2013-12-05 2019-03-12 Givaudan Sa Organic compounds
EP4534135A3 (de) 2014-08-26 2025-06-11 Stryker Corporation Nasenimplantate sowie systeme und verfahren zur verwendung
CA2996673A1 (en) 2015-09-25 2017-03-30 Spirox, Inc. Nasal implants and systems and method of use
US12046341B2 (en) 2021-10-05 2024-07-23 Bradford Rabin Methods and systems for electronically adjusting a dosing pattern of a patient undergoing a medical regimen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
FR2684101B1 (fr) * 1991-11-22 1993-12-31 Adir Cie Nouveaux derives de benzoate d'ethanolamine, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5543405A (en) * 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity
US5498629A (en) 1993-12-23 1996-03-12 Ortho Pharmaceutical Corporation Anticonvulsant pseudofructopyranose sulfamates
US5753693A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
US5795895A (en) * 1997-06-13 1998-08-18 Anchors; J. Michael Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування

Also Published As

Publication number Publication date
DE60035870T2 (de) 2008-05-08
CA2686633A1 (en) 2000-12-21
EP2305228B1 (de) 2015-05-06
EP1187603A4 (de) 2004-02-11
EP2305227A1 (de) 2011-04-06
CA2377330A1 (en) 2000-12-21
ES2542892T3 (es) 2015-08-12
ES2542891T3 (es) 2015-08-12
EP2305227B1 (de) 2015-05-06
WO2000076493A1 (en) 2000-12-21
EP2305226A1 (de) 2011-04-06
EP2305226B1 (de) 2015-05-06
AU770068B2 (en) 2004-02-12
CY1106974T1 (el) 2012-09-26
EP1187603A1 (de) 2002-03-20
EP2308481B1 (de) 2015-05-06
EP2305228A1 (de) 2011-04-06
ES2542868T3 (es) 2015-08-12
AU5489600A (en) 2001-01-02
CA2377330C (en) 2009-11-24
PT1187603E (pt) 2007-11-16
DK1187603T3 (da) 2007-12-17
DE60035870D1 (de) 2007-09-20
EP2308481A1 (de) 2011-04-13
EP1187603B1 (de) 2007-08-08
ES2291215T3 (es) 2008-03-01

Similar Documents

Publication Publication Date Title
ATE369126T1 (de) Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
PT1333887E (pt) Metodo de tratamento de desordens musculares
MXPA03009772A (es) Metodos y composiciones para tratar lesiones orales y del esofago.
WO2003030823A3 (en) Combinations for the treatment of immunoinflammatory disorders
EP0824917A3 (de) Verwendung eines Serotonin 5-HT1F Agonists zur Herstellung eines Wirkstoffs für die Behandlung oder die Verbesserung des Schnupfens oder der allergischen Rhinitis
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
BRPI0408491A (pt) tratamento da doença de alzheimer
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
JO3446B1 (ar) طريقة لمعالجة الأرق الأولي
DE69303305D1 (de) Mittel zur Behandlung chronischer Ermüdungserscheinungen
DK1156795T3 (da) Anvendelse af ravsyre eller salte deraf, og fremgangsmåde til behandling af insulinresistens
EP1825851A3 (de) Kombinationstherapie zur Gewichtsreduzierung und Fettleibigkeitsbehandlung
BR0015121A (pt) Composição farmacêutica utilizável para o tratamento de inflamação em humanos, e, método de tratamento de inflamação
DK1140119T3 (da) Anvendelse af heparin med lav molekylvægt til forebyggelse og/eller behandling af motorneuronale sygdomme
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
NO20053023L (no) Synergistisk kombinasjon omfattende roflumilas og (R,R)-formoterol
WO2004100899A3 (en) Use of secretin in treatments of disorders associated with the amygdala
BRPI0407574A (pt) combinações farmacêuticas que compreendem um inibidor de nos e um antagonista de receptor de nmda

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1187603

Country of ref document: EP